Company leader
Maulik Nanavaty
Chief Executive Officer
Anumana
Maulik Nanavaty is chief executive of Anumana, the Cambridge, Massachusetts company founded by nference and Mayo Clinic that uses AI to find hidden heart disease in standard 12-lead ECGs. He spent more than three decades in medical devices at Baxter and Boston Scientific before joining Anumana.
Pharmaceutical Science and Baxter
Nanavaty earned a PhD in pharmaceutical sciences from the University of Illinois and an MBA from the University of Chicago. He spent 16 years in executive roles at Baxter International. He told Pulse 2.0 that Baxter gave him a foundation in global healthcare systems through roles in medical devices, pharmaceuticals, and biologics.
Eighteen Years at Boston Scientific
At Boston Scientific he worked in interventional cardiology and neuromodulation. He was vice president and general manager of Interventional Cardiology for Boston Scientific Japan, then president of Boston Scientific Japan, and finally senior vice president and president of Neuromodulation, a business with more than $1 billion in revenue that makes implantable devices for neurological conditions, according to his Anumana biography.
Leading Anumana
Anumana appointed Nanavaty CEO in October 2023, soon after FDA clearance of its first algorithm, ECG-AI LEF. He also serves as president of ventures at nference and CEO of Vimana. Under his leadership Anumana won CMS reimbursement for ECG-AI LEF, began commercial deployment in 2025, and added FDA clearances for pulmonary hypertension and, in April 2026, cardiac amyloidosis.
"The more conditions we can identify from a single ECG, the more valuable the test becomes in clinical practice," he said when the amyloidosis clearance was announced. In the Pulse 2.0 interview he described reimbursement as a critical step for adoption: without it, he said, even the most advanced AI faces trouble scaling.